PharmaVoice
JULY 9, 2025
Today, we’re speaking to Simone Steiner, Transgene’s new chief technology officer, about how the company is transitioning from early- to late-stage testing and advancing its manufacturing capabilities Oncology vaccines are gaining traction in the clinic as potential game changing treatments for cancer.
Pharma Times
JULY 1, 2025
The vaccine showed a 26.6% higher relative vaccine efficacy compared with the existing option. Across all age groups, risk profiles and vaccination histories, the results were consistently strong. The severity of this past flu season underscores the need for more effective vaccines.” for A/H1N1, 22.2% for B/Victoria.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 20, 2025
Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.
Pharmacy Times
JUNE 24, 2025
What I like about this conference is it's pharmacists pulling out the abstracts, it's pharmacists presenting the abstracts, and it's a panel discussion of that abstract by pharmacists. So it's ASCO from a pharmacist perspective. And I like that. It's disease-state focused.
Pharmacy Times
JUNE 20, 2025
She also discusses HOPA and its partnership with Pharmacy Times in providing cutting-edge information, expressing admiration for the Oncology Pharmacist Connect (OPC) conference's rapid dissemination of relevant information and high-quality presentations. Pharmacy Times : Can you discuss your career experience as an oncology pharmacist?
Express Pharma
JUNE 19, 2025
Indian pharmaceutical companies supply more than 60 per cent of global demand for vaccines and over 40 per cent of generic medicines consumed in the United States (2). This growth is further driven by global shortages of sterile products, an expanding biologics pipeline, and the demand for emergency-use therapies including vaccines.
Pharmacy Times
JUNE 27, 2025
Patients often present with peripheral blood, bone marrow, and splenic involvement. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. There is currently no universal standard of care for MCL.
Expert insights. Personalized for you.
179 
Let's personalize your content